Ipsen

Exelixis and Ipsen announced the initiation of COSMIC-312, a phase 3 trial comparing cabozantinib with atezolizumab against sorafenib for previously untreated advanced hepatocellular carcinoma. The trial will also assess cabozantinib as a single agent in the first-line setting.

A matching-adjusted indirect comparison found that Cabometyx (cabozantinib) increased median progression-free survival by 80.6% compared with regorafenib in second-line treatment of advanced hepatocellular carcinoma.

With a median follow-up of two years, Cabometyx combined with Opdivo showed superior progression-free survival, overall survival, and objective response rate versus sunitinib. A separate CheckMate -9ER2 analysis reported improved health-related quality of life versus sunitinb.

Ipsen offers careers in a variety of fields and provides listings of job opportunities.

The page describes Ipsen’s culture and values and their relationship to its commitment to innovation and improving patient outcomes in the biopharmaceutical industry.

Here at Ipsen, there are endless challenges and rewards. Opportunities across the globe. A team empowered by collaboration.

The page introduces Ipsen’s Executive Leadership Team and Board of Directors.

Neuroscience is a strategic driver for Ipsen, which is expanding its pipeline into neurodegenerative disorders through external innovation.

Fondation Ipsen is a non-for-profit foundation dedicated to raise awareness of rare diseases and promote their early detection and diagnosis.

Ipsen is a global pharmaceutical company that aims to prolong patients’ lives, improve health outcomes, and create a positive impact for patients and society.

Ipsen provides information and assistance related to its services and initiatives.

after clicking the copy button contact informnation getting copied

Ipsen has a global presence and locations around the world.

Ipsen provides a channel for medical information requests and reports of adverse events or complaints through Ipsen Medical Information or globalmedinfo@ipsen.com.

Ipsen is a global biopharmaceutical company focused on innovation and specialty care to improve the lives of patients around the world.

Ipsen announced comparative data from a matching-adjusted indirect comparison of second-line treatments for advanced hepatocellular carcinoma. The analysis found that Cabometyx (cabozantinib) increased median progression-free survival by 80.6% compared with regorafenib.

The page provides the terms and conditions for the Ipsen corporate website, supplied by Ipsen Pharma.